GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stryker Corp (NYSE:SYK) » Definitions » Debt-to-EBITDA

Stryker (Stryker) Debt-to-EBITDA : 2.15 (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Stryker Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stryker's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,094 Mil. Stryker's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10,901 Mil. Stryker's annualized EBITDA for the quarter that ended in Dec. 2023 was $6,052 Mil. Stryker's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Stryker's Debt-to-EBITDA or its related term are showing as below:

SYK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.57   Med: 2.82   Max: 4.58
Current: 2.63

During the past 13 years, the highest Debt-to-EBITDA Ratio of Stryker was 4.58. The lowest was 1.57. And the median was 2.82.

SYK's Debt-to-EBITDA is ranked worse than
68.6% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs SYK: 2.63

Stryker Debt-to-EBITDA Historical Data

The historical data trend for Stryker's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Debt-to-EBITDA Chart

Stryker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.01 4.58 3.39 3.23 2.63

Stryker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.60 3.29 2.64 2.64 2.15

Competitive Comparison of Stryker's Debt-to-EBITDA

For the Medical Devices subindustry, Stryker's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stryker's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stryker's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stryker's Debt-to-EBITDA falls into.



Stryker Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stryker's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2094 + 10901) / 4934
=2.63

Stryker's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2094 + 10901) / 6052
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Stryker  (NYSE:SYK) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Stryker Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stryker's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stryker (Stryker) Business Description

Address
2825 Airview Boulevard, Kalamazoo, MI, USA, 49002
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Executives
Srikant Datar director ICF INTERNATIONAL, INC., 9300 LEE HIGHWAY, FAIRFAX VA 22031
Berry William E Jr officer: Vice President, Controller 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Kevin Lobo officer: Group Pres., Neurotech & Spine STRYKER, 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Viju Menon officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Allan C. Golston director 2825 AIRVIEW BLVD., KALAMAZOO MI 49002
Ronda E Stryker director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher officer: VP, Chief Legal Officer 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
James Andrew Pierce officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Glenn S Boehnlein officer: Vice President, CFO 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink officer: VP, Global Human Resources 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Spencer S Stiles officer: Group President 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Timothy J Scannell officer: Group President 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Roch Doliveux director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine Ann Owen officer: VP 2825 AIRVIEW BLVD., KALAMAZOO MI 49002

Stryker (Stryker) Headlines

From GuruFocus

Stryker Corp To Host Investor Day Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Stryker Corp Corporate Analyst Meeting Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2020 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2020 Stryker Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024